Investment
Features
FeesSafety
Academy
More
Pluang+

Sony-backed S.BLOX lists Cardano's ADA and NIGHT tokens, expanding Cardano's presence in Japan.

Market News
24 Aug 2026
Tokenpost
View Source
Bullish
Sony-backed S.BLOX lists Cardano's ADA and NIGHT tokens, expanding Cardano's presence in Japan.

Sony Group-owned crypto exchange S.BLOX has added Cardano's ADA and Midnight's privacy-focused NIGHT token to its trading platform, marking a significant expansion for Cardano in Japan. This listing is notable given Japan's strict cryptocurrency regulations and limited domestic exchange options. S.BLOX is the first Japanese exchange to support NIGHT, offering promotional campaigns for both tokens. This move strengthens Cardano and Midnight's foothold in Japan, providing local investors greater access to these ecosystems.

More News

Anteris gets German clearance to expand global PARADIGM heart valve trial, boosting patient recruitment.

Anteris gets German clearance to expand global PARADIGM heart valve trial, boosting patient recruitment.

Anteris Technologies received regulatory approval from Germany's BfArM to start enrolling patients in its global PARADIGM trial for the DurAVR Transcatheter Heart Valve. This approval allows the company to recruit patients at leading German centers, ...

Market News
Bullish
1 hour ago
XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech announced positive final efficacy results from its phase II TASKIN trial for vilamakitug (XB2001) in refractory metastatic colorectal cancer. The study, funded by the French National Cancer Institute, showed a 61.3% overall survival rate at ...

Company Fundamentals
Bullish
4 hours ago
Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

XBiotech announced positive final results from the Phase II TASKIN study, showing that adding Vilamakitug (XB2001) to standard chemotherapy improved 12-month overall survival to 61.3% in patients with refractory metastatic colorectal cancer, surpassi...

Market News
Bullish
4 hours ago
Jio Platforms' IPO anchor book oversubscribed 30x with $26.3B bids from top global investors

Jio Platforms' IPO anchor book oversubscribed 30x with $26.3B bids from top global investors

Jio Platforms, backed by Meta and Google, has seen its IPO anchor book oversubscribed over 30 times, attracting $26.3 billion in bids for an $854 million portion. The company aims to raise up to $3.2 billion in India's largest-ever IPO by rupee value...

Market News
Bullish
4 hours ago
Hyperliquid (HYPE) tops Bitcoin and Ether in 30-day analyst sentiment index, signaling strong market outlook.

Hyperliquid (HYPE) tops Bitcoin and Ether in 30-day analyst sentiment index, signaling strong market outlook.

Hyperliquid (HYPE) has surpassed Bitcoin (BTC) and Ether (ETH) in a 30-day analyst sentiment index, indicating a more positive outlook from market analysts over the past month. The index, which updates hourly and counts one vote per analyst, measures...

Analyst Insights
Neutral
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App